Tibet Weixinkang Medicine Co., Ltd.

Equities

603676

CNE100002QQ3

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
8.76 CNY +3.30% Intraday chart for Tibet Weixinkang Medicine Co., Ltd. +13.32% -16.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tibet Weixinkang Medicine Co., Ltd.(XSSC:603676) added to S&P Global BMI Index CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tibet Weixinkang Medicine Unit Gets Certification for Dopamine Drug in China MT
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the First quarter Ended March 31, 2021 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Zhejiang China Commodities City : China stocks end higher on upbeat data RE
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Certain A Shares of Tibet Weixinkang Medicine Co., Ltd. are subject to a Lock-Up Agreement Ending on 21-JUL-2020. CI
Tibet Weixinkang Medicine Co., Ltd. Announces Implementation of Rights and Interests Distribution Per A Share for 2019, Payable on June 2, 2020 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019 CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019 CI
Tibet Weixinkang Medicine Co., Ltd. Announces Implementation of Rights and Interests Distribution for 2018, Payable on May 30, 2019 CI
Tibet Weixinkang Medicine Co., Ltd. Announces Earnings Results for the First Quarter of 2019 CI
Tibet Weixinkang Medicine Co., Ltd. Announces Earnings Results for 2018 CI
Chart Tibet Weixinkang Medicine Co., Ltd.
More charts
Tibet Weixinkang Medicine Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical medicines and related active pharmaceutical ingredients (APIs). The Company's main products include injection of complex vitamins, injection of potassium aspartate magnesium, sucrose iron injection and potassium aspartate injection. The Company is also engaged in the production and sales of liver protection drugs and antibiotics products. The Company mainly distributes its products in the domestic market.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 603676 Stock
  4. News Tibet Weixinkang Medicine Co., Ltd.
  5. Tibet Weixinkang Medicine Unit Gets Certification for Dopamine Drug in China